Komori
Fuso Pharmaceutical Industries (4538) · FactFull-year gain on sale of fixed assets updated

Recognition of Gains on Sale of Owned Real Estate

First written in FY2017-Q3. 3 of 10 entries say "Restated". Latest entry: FY2021.

10entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2017-Q3 – FY20212017: 220172018: 220182019: 220192020: 220202021: 22021
Same theme, other companies
Extraordinary Gains and Losses from the Sale and Disposal of Fixed AssetsA theme 209 companies write about · 31 as a headwind · 182 as a tailwind

81 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 175 companies compared. The sentences above are computed from all 175.Comparing 200 of the theme's 238 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2021Full-year gain on sale of fixed assets updatedAnnual report

    「Gain (loss) on sale of fixed assets (△ indicates a gain) △91」

    The FY2021 full-year statement of cash flows records a ¥91 million gain on the sale of fixed assets.
  2. FY2021-Q3RestatedAnnual report

    「Gain on sale of fixed assets 38 91」

    This reconfirms that the gain on the sale of fixed assets during the cumulative third-quarter period was ¥91 million, up from ¥38 million in the same period of the previous year.
  3. FY2021-Q2Second-quarter gain on sale of fixed assets updatedAnnual report

    「Gain on sale of fixed assets 38 91」

    The gain on the sale of fixed assets during the cumulative second-quarter period was ¥91 million, up from ¥38 million in the same period of the previous year.
  4. FY2020-Q3Third-quarter gain on sale of fixed assets updatedAnnual report

    「Gain on sale of fixed assets - 38」

    During the cumulative third-quarter period, a ¥38 million gain on the sale of fixed assets was recognized as an extraordinary gain. The latest disclosure does not specifically state that this was a real estate sale.
  5. FY2019Cited as achievedAnnual report

    「Meanwhile, net income was ¥894 million, down ¥75 million, or 7.7%, from the same period of the previous year, when a gain on the sale of fixed assets consisting of owned real estate was recognized as an extraordinary gain.」

    The gain on the sale of owned real estate in the same period of the previous year is cited as a factor behind the year-on-year decline in net income when comparing historical results.
  6. FY2019-Q3Cited as achievedAnnual report

    「Meanwhile, quarterly net income was ¥873 million, down ¥69 million, or 7.4%, from the same quarter of the previous year, when a gain on the sale of fixed assets consisting of owned real estate was recognized as an extraordinary gain.」

    The gain on the sale of owned real estate recognized in the same quarter of the previous year is cited as a factor behind the decline in net income for the cumulative third-quarter period when comparing historical results.
  7. FY2018RestatedAnnual report

    「As a result of recognizing a ¥567 million gain on the sale of fixed assets consisting of owned real estate as an extraordinary gain,」

    This reconfirms that the ¥567 million gain on the sale of fixed assets consisting of owned real estate was recognized as an extraordinary gain for the full year.
  8. FY2018-Q3Gain on sale of fixed assets updatedAnnual report

    「A gain of ¥567 million on the sale of fixed assets consisting of owned real estate was recognized as an extraordinary gain.」

    During the cumulative third-quarter period, a ¥567 million gain on the sale of fixed assets consisting of owned real estate was recognized as an extraordinary gain.
  9. FY2017RestatedAnnual report

    「A gain of ¥477 million on the sale of fixed assets consisting of owned real estate was recognized as an extraordinary gain.」

    This reconfirms that the ¥477 million gain on the sale of fixed assets consisting of owned real estate was recognized as an extraordinary gain for the full year.
  10. FY2017-Q3First statedAnnual report

    「A gain of ¥477 million on the sale of fixed assets consisting of owned real estate was recognized as an extraordinary gain.」

    During the cumulative third-quarter period, a ¥477 million gain on the sale of fixed assets consisting of owned real estate was recognized as an extraordinary gain.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Recognition of Gains on Sale of Owned Real Estate | Fuso Pharmaceutical Industries,Ltd. (4538) | Komori